Clinical outcomes and prognostic factors of stereotactic body radiation therapy in metastatic nasopharyngeal carcinoma
Background: The prognosis for metastatic nasopharyngeal carcinoma (mNPC) remains poor, and effective treatment options are still limited. Objectives: This study aims to evaluate the efficacy of stereotactic body radiation therapy (SBRT) and identify prognostic factors in patients with mNPC. Design:...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-06-01
|
| Series: | Therapeutic Advances in Medical Oncology |
| Online Access: | https://doi.org/10.1177/17588359251351226 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Background: The prognosis for metastatic nasopharyngeal carcinoma (mNPC) remains poor, and effective treatment options are still limited. Objectives: This study aims to evaluate the efficacy of stereotactic body radiation therapy (SBRT) and identify prognostic factors in patients with mNPC. Design: A retrospective study. Methods: From August 2019 to November 2023, this retrospective study included 62 mNPC patients with 84 metastatic lesions treated with SBRT. The primary endpoint was progression-free survival (PFS). PFS1, PFS2, and overall survival (OS) were also assessed, and related prognostic factors were analyzed. Results: The median follow-up time from the diagnosis of metastasis was 44 months (range from 12 to 85 months). Combining SBRT with systemic therapy resulted in favorable survival outcomes, with 3-year PFS, PFS1, PFS2, OS, and local control rates of 35.5%, 35.7%, 56.1%, 87.2%, and 86.5%, respectively. The combination of SBRT with first-line systemic therapy, disease control before SBRT, oligometastatic disease, and SBRT to all metastatic lesions exhibited superior PFS, PFS1, and PFS2. Multivariable analysis indicated that the line of SBRT treatment was a predictor of PFS1 and PFS2, and SBRT to all metastatic lesions was a predictor of all PFSs. Conclusion: SBRT is an effective and safe local treatment for mNPC patients. Early intervention with SBRT during first-line therapy and SBRT to all metastatic sites for oligometastatic disease may help improve disease control. |
|---|---|
| ISSN: | 1758-8359 |